Aerovate Therapeutics IPO Advisory
Share this IPO Profile:Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on Aerovate Therapeutics, and our comprehensive analysis, click "Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Aerovate Therapeutics | AVTE - NASDAQ |
$13.00-$15.00 | $14.00 | $28.00 | 8.7 million | 6/30/2021 |
| Jefferies, Cowen, Evercore | ||||||
Co-Manager(s): Wedbush PacGrow | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-06-09 Terms Added 2021-06-24 | ||||||
Aerovate Therapeutics Quote & Chart - Click for current quote - AVTE
IPO Boutique aggregates information on public companies and private companies, such as "AVTE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Aerovate Therapeutics (adapted from Aerovate Therapeutics prospectus):
They are a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "AVTE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.